Phase 3 Trial Methods in the Assessment of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors

Conference|ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the methods used during the phase 3 trial to assess lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 ASCO Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.

During the discussion, Strosberg details the methods used for the phase 3 trial to assess lutetium Lu 177 dotatate as a treatment for patients with advanced midgut neuroendocrine tumors.